コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 or the treatment of ocular manifestations of Behcet's disease.
2 eitis, and finally, somewhat controversially Behcet's disease.
3 enic pathways in the spondyloarthritides and Behcet's disease.
4 on in the management of venous thrombosis in Behcet's disease.
5 fied 5 novel genetic susceptibility loci for Behcet's disease.
6 ve emerged as a successful approach to treat Behcet's disease.
7 venile idiopathic arthritis, sarcoidosis and Behcet's disease.
8 d the International Study Group criteria for Behcet's disease.
9 ss in patients with a familial occurrence of Behcet's disease.
10 her characteristic or diagnostic features of Behcet's disease.
11 s disease, systemic lupus erythematosus, and Behcet's disease.
12 iant cell arteritis, Takayasu arteritis, and Behcet's disease.
14 95% confidence interval [CI], 0.19-0.74) and Behcet's disease (aHR, 0.10; 95% CI, 0.01-0.85) were ass
16 a number of inflammatory diseases, including Behcet's disease and age-related macular degeneration.
17 lvement of other autoimmune diseases such as behcet's disease and ankylosing spondylitis, and ocular
18 the genetic association between HLA-B*51 and Behcet's disease and exploring additional susceptibility
19 cause monogenic recessive diseases: MEFV in Behcet's disease and Henoch-Schonlein purpura, and A1AT
20 (GWAS) in vasculitis have been published, in Behcet's disease and Kawasaki disease; none of the genes
21 as demonstrated efficacy in the treatment of Behcet's disease and other forms of posterior uveitis.
22 udy is the first systematic genome screen in Behcet's disease and provides evidence of linkage to sev
25 ious uveitides (the ocular manifestations of Behcet's disease and sarcoidosis) based on multicolor fl
31 chemokines and its receptor in patients with Behcet's disease (BD) and their associations with diseas
32 ssociated with the autoinflammatory disorder Behcet's disease (BD) in epistasis with HLA-B*51, which
50 atients (n = 52, F:M = 40:12), patients with Behcet's disease (BD, n = 40, F:M = 29:11) as another sy
51 r uveitis cases included diagnosis with JIA, Behcet's disease, bilateral uveitis, history of cataract
53 with 311,459 SNPs in 1,215 individuals with Behcet's disease (cases) and 1,278 healthy controls from
55 correlated with disease activity in terms of Behcet's Disease Current Activity Form (BDCAF) (p < 0.00
56 und in the peripheral blood of patients with Behcet's disease during episodes of ocular inflammation.
57 NCA)-associated vasculitis, Crohn's disease, Behcet's disease, eosinophilic granulomatosis with polya
59 anding knowledge on large vessel problems in Behcet's disease, highlighting recent contributions.
62 ed the genetic association between UBAC2 and Behcet's disease in 3 independent sets of patients and c
70 gest that the robust HLA-B*51 association in Behcet's disease is explained by a variant located betwe
74 gly, allotype 10, previously associated with Behcet's disease, is consistently a low-activity outlier
76 current aphthous stomatitis on the mild end, Behcet's disease on the severe end, and PFAPA intermedia
77 ared to ankylosing spondylitis (p = 0.0001), behcet's disease (p = 0.0001), presumed latent tuberculo
78 pect to ankylosing spondylitis (p = 0.0001), behcet's disease, (p = 0.0001) presumed latent tuberculo
81 ng recurrent aphthous stomatitis, PFAPA, and Behcet's disease, placing these disorders on a common sp
82 olving patients with ankylosing spondylitis, behcet's disease, presumed sarcoidosis, presumed latent
87 a patient who had a vasculopathy fitting the Behcet's disease type, but who lacked the other characte
91 ulitis occurs in a subgroup of patients with Behcet's disease who are at high risk for disease-relate
93 ave shown an increased rate of thrombosis in Behcet's disease, with a different clinical presentation